The molecular diagnosis solution offered by AMS Laborator Genetic addresses a significant medical need, unmet with timely and actionable information, that addresses the challenges of the current standard of care for diagnosing prostate cancer. The Select MDx test helps identify patients at high risk for aggressive prostate cancer, thus helping to select men for prostate biopsy.
SelectMDx,an urine test that helps identify men at risk for aggressive prostate cancer before the initial biopsy.
1 Haese, A, et al. (2019) Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy. J Uro. doi: 10.1097/JU.0000000000000293
2 Govers TM, et al. (2018) Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment. J Urol. doi: 10.1016/j.juro.2018.07.034
3 Govers TM, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases. doi: 10.1038/s41391-018-0076-3
4 Trooskens G, et al. (2018) Robust performance of a Urinary Molecular Biomarker–Based Risk Score to detect High-grade Prostate Cancer using optimized cascading models. In: Global Congress on Prostate Cancer; 2018 Jun 28-30; Frankfurt, Germany.
5 Shore N, et al. (2018) SelectMDx Impacts Prostate Biopsy Decision-making in Routine Clinical Practice. Urology Practice. doi: 10.1016/j.urpr.2018.09.002.
6 Trooskens G, et al. (2018) Assessment of an established TRUS and a urinary biomarker-based risk score as an inclusion criteria for multiparametric MRI to detect clinically significant prostate cancer. In: Global Congress on Prostate Cancer; 2018 Jun 28-30; Frankfurt, Germany.
7 Van Neste L, et al. (2016) Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol, Nov; 70(5): 7 40-7 48.
8 Hendriks RJ, et al. (2017) A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. The Prostate, 77(14):1401-1407.
9 Hessels D, et al. (2017) Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. Translational Medicine Communications, 2:5. doi: 10.1186/ s41231-017-0014-8.
10 Dijkstra S, et al. (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. BJU Int, 120(5):659-665. doi: 10.1111 /bju.13861.
11 Alinezhad S, et al. (2016) Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 11 (5): e0155go1. doi: 10.1371/journal.pone.0155901.
12 Leyten GH, et al. (2015) Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res, 21 (13):3061-70.
13 Vinarskaja A, et al. (2011) DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers, 3:3714-3725. doi: 10.3390/cancers3043714.